ACADIA Pharmaceuticals Inc. (ACAD) stock price moved 0.34% away from 20-Days Simple Moving Average, -16.57% from 50-Days Simple Moving Average and separated -38.26% from 200 Days Simple Moving Average. ACADIA Pharmaceuticals Inc. (ACAD) reported loss -2.32% in recent buying and selling session with closing price of $ 18.11. The stock’s traded 1.76 million shares in session while it holds an average volume of 3.22 million shares. The ACAD switched 24.81% away from its 52 week minimum and distanced -56.04% from its 52 week peak. The volatility change in the previous week has observed by 7.09% and experienced of 7.78% change in the last month.
The short ratio in the company’s stock is documented at 4.10 and the short float is around of 10.63%. Beta factor, which measures the riskiness of the security, was registered at 3.34. The Company kept a record of 124.23 million floated shares and 124.73 million shares outstanding. The average true range of the stock is observed at 1.44 and the relative strength index of the stock is recorded at 46.18.
Analyst notified mean rating at 2.00 after consensus analysis. (Rating Scale: 1.0 Strong Buy, 2.0 Buy, 3.0 Hold, 4.0 Sell, 5.0 Strong Sell). Keep in mind that Investors should not rely only on an analyst’s recommendation when taking a decision whether to buy, hold, or sell a stock. Instead, they should also do their own research—such as reading the prospectus for new companies or for public companies, the quarterly and annual reports filed with the SEC—to confirm whether a particular investment is appropriate for them in light of their individual financial circumstances.
ACADIA Pharmaceuticals Inc. (ACAD) Stock Profitability Levels:
Gross profit margin is 92.70%. The larger the gross profit margin, the better for the company. Its return on investment ratio was -67.00% in the trailing 12 months period.
The Company’s sales have grown at an average annualized rate of about 91.10% during the past five years. For the past 5 years, The Company’s EPS growth has been nearly -36.60%. Looking out over a next 5-year period, analysts expect the company to see its earnings go up by 38.30%, annually. Analyst established EPS growth expected to grow of 23.20% for this year and EPS growth for next year is likely to attain at 66.70%.
Looking about the past performance history, the company plunged 9.89% for the last five trades and expanded 9.76% in one month period. The stock deteriorated -37.12% during the past three month period and discounted -49.48% in half year. During the yearly overview it downgraded -43.03% and Showed -39.85% year to date performance.
I am Sharon Davenport and I’m passionate about business and finance news with over 4 years in the industry starting as a writer working my way up into senior positions. I am the driving force behind nasdaqexpress.com with a vision to broaden the company’s readership throughout 2016. I am an editor and reporter of “Healthcare” category.